February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
A Pennsylvania compounding pharmacy received an FDA warning letter for cGMP violations, indicating heightened FDA scrutiny on compounding facilities.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Compounding outsourcing facilities (503B) and other compounding pharmacies should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; ongoing compliance improvements should be prioritized within 30 days.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued a warning letter to a Pennsylvania compounding pharmacy for significant cGMP deviations, signaling increased enforcement risk.
Who it affects
Compounding outsourcing facilities (503B) and other compounding pharmacies
What you must do
Review and strengthen cGMP compliance programs, especially for sterile compounding, and prepare for potential FDA inspections.
Deadline
Immediately; ongoing compliance improvements should be prioritized within 30 days.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- GLP‑1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters - JD Supra
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)